A Phase 2 Study of the MET RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck.
Latest Information Update: 06 Jul 2023
At a glance
- Drugs Foretinib (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GSK
- 11 Nov 2009 Actual end date (1 May 2009) added as reported by ClinicalTrials.gov.
- 11 Nov 2009 Actual end date (1 May 2009) added as reported by ClinicalTrials.gov.
- 26 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.